Increased granulocyte neprilysin (CD10) expression is associated with better prognosis in patients with heart failure with reduced ejection fraction

25 May 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Henrike Arfsten

Medical University of Vienna, Vienna (Austria)

11 More presentations in this session

Presentation thumbnail

Dual Regulation of SUMO2 and STAT1 by HectD3 Protects Heart from Hypertrophy and Inflammation

Doctor A. Rangrez (Kiel, DE)

Presentation thumbnail

A translational mouse model of HFpEF

Mr A. Withaar (Groningen, NL)

Abstract Slides Video

Presentation thumbnail

Diastolic dysfunction and HFpEF characteristics are exacerbated with ageing in smoothelin-like 1 (SMTNL1)-deficient mice

Ms M. Murali (Calgary, CA)

Abstract Slides Video

Presentation thumbnail

L-2-hydroxyglutarate dehydrogenase (L2HGDH) is a novel metabolic target protecting from cardiac hypertrophy and heart failure

Doctor A. Remes (Kiel, DE)

Abstract Slides Video

Presentation thumbnail

Purified exosome product and extracellular vesicles: treatment for acute myocarditis, dilated cardiomyopathy and heart failure

Doctor K. Bruno (Jacksonville, US)

Abstract Slides Video

Access the full session

Session thumbnail

Rapid Fire 1 - Basic Science

The Event

Heart Failure 2019

25 May - 28 May 2019

You may be interested in

Congress Presentation

Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.

Congress Presentation

Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy

Congress Session

Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources